Business Management Articles | Page 2

FDA Grants Bevacizumab Full Approval for Glioblastoma
The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy.
FDA Approves Trastuzumab Biosimilar
The FDA has approved the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst), which now has has approved indications for HER2-positive patients with breast or metastatic gastric or gastroesophageal junction adenocarcinoma.
Plan Now for MIPS Reporting in 2018
The end of the year is always hectic for oncology practices, but 2017 is proving exceptionally busy as CMS' Quality Payment Program transitional year comes to a close.
In a recent interview with Oncology Business ManagementTM, Peter Aran, MD, medical director of population health management for BlueCross BlueShield of Oklahoma, discussed participation in the Oncology Care Model from CMS, which is designed to improve the quality and value of care.
As CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, the results from a new study show that cancer treatment remains much less expensive at community oncology clinics than at hospitals and that the spending gap between the 2 types of sites may be growing wider.
Oncology providers contend that the sweeping $1.5 trillion in tax cuts sought by Republicans would trigger sequester cuts that would drive more independent practices out of business and reduce patient access to care.
FDA Approves Adjuvant Sunitinib for High-Risk RCC
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.
FDA Authorizes Tumor Assay Through New Streamlined Pathway
The FDA announced that it has approved the IMPACT tumor profiling assay, while also making it easier for some device manufacturers to bring their products to market.
Bayer, Loxo to Collaborate on Larotrectinib
Bayer and Loxo Oncology have entered into a partnership to develop and market larotrectinib (LOXO-101) and LOXO-195 in the United States and worldwide.
Surgery in Oncology Is Not Always a Simple Decision
The personalization of cancer care is more elaborately expressed in multidisciplinary tumor conferences and clinical trials.
Publication Bottom Border
Border Publication